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locoregional right-sided breast cancer treatment in this 
study, a slightly lower risk of pneumonitis and secondary lung 
cancer (in ever-smoking patients) can be expected. In 
addition, we estimate that for 10-25% of the patients the 
heart dose will also be reduced. We therefore suggest to also 
apply breath-hold for locoregional irradiation (with and 
without IMN) of patients with right-sided breast cancer. 
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Purpose or Objective: A large recent study( 1) has shown 
that in patients with early-stage breast cancer, irradiation of 
the regional (internal mammary and medial supraclavicular) 
nodes improves disease-free and distant disease-free 
survival, while breast-cancer mortality is reduced. However, 
internal mammary nodes (IMN) are usually delineated using 
anatomical landmarks, e.g. using the ESTRO delineation atlas 
(2), since the nodes are not visible on CT. We studied the 
impact of SPECT-CT lymphoscintigraphy on the localisation of 
IMN and on the subsequent treatment planning and dose 
distribution.  
 
Material and Methods: For 10 breast cancer patients (5 right, 
5 left), SPECT-CT lymphoscintigraphy of the IMN was 
performed. Using the Eclipse TPS (Varian), the SPECT-CT and 
planning CT images were co-registered. The 70% of the 
maximum uptake value was used to contour the IMN on 
SPECT-CT images. Using the ESTRO atlas, the IMN were also 
contoured on the planning CT images. The localisation of IMN 
based on the SPECT-CT images and based on the ESTRO atlas 
were compared, as well as treatment plans based on the two 
contouring methods.  
 
Results: For 2 patients, no drainage to the IMN was visible. 
For 6 out of the remaining 8 patients, the caudal border of 
the IMN based on SPECT-CT was situated at the second 
intercostal (IC) space, whereas the ESTRO atlas prescribes to 
include the third or fourth IC space depending of the position 
of the tumour in the breast. In the lateral direction, the 
lymph nodes mostly follow the veins, but for one patient, the 
position on SPECT-CT was more medial (and missed by the 
ESTRO atlas) and for one more lateral. On treatment 
planning, for one patient only 50% of the IMN seen on SPECT-
CT would have been covered following contouring using the 
ESTRO atlas. The mean heart dose (MHD) increased by 0.8 Gy 
for one patient and decreased by 1.0 Gy for one patient and 
the mean lung dose (MLD) decreased by 2 Gy for one of the 
patients following SPECT-CT based delineation. For the other 
patients, the differences in MHD and MLD were less than 0.5 
Gy.  
 
Conclusion: Delineation of the IMN using SPECT-CT 
lymphoscintigraphy is easier and less user dependent than 
using the delineation atlas. In general, the agreement 
between atlas and SPECT-CT based delineation is good. 
However, the caudal border of the IMN was overestimated in 
6 out of 8 patients. Differences in the medial border were 
also observed, resulting in underdosage of the IMN in 1 and 
overdose to lung and heart in 1 other patient. SPECT-CT 
lymphoscintigraphy might be applied for patients with a high 
heart dose, to investigate whether the caudal and medial 
border of the IMN may be reduced.  
(1) Poortmans PM, et al. Internal Mammary and Medial 
Supraclavicular Irradiation in Breast Cancer. N Engl J Med 
2015; 373:317-327.  
(2) Offersen BV, et al. ESTRO consensus guideline on target 
volume delineation for elective radiation therapy of early 
stage breast cancer. Radiother Oncol 2015 Jan;114(1):3-10. 
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Purpose or Objective: Increased biological information on 
individual tumors can be obtained with 21-gene recurrence 
score (RS) testing, which has revolutionized receipt of 
chemotherapy. Similar biological drivers of outcomes may be 
useful in determining who might benefit from post-
mastectomy radiation, as is being investigated in the 
SUPREMO and other trials. This study aimed to determine 
who was getting post-mastectomy radiation in a T2N0 cohort, 
as well as whether the recurrence test score affected 
radiation radiation therapy receipt. 
 
Material and Methods: The National Cancer Data Base 
captures about 75% of all US cancer patients and was queried 
for breast cancer patients from 2004-2012. 5302 T2N0 post-
mastectomy patients were identified. Multivariate logistic 
regression analysis was used to estimate the covariates 
associated with test utilization and impact on radiation 
therapy decisions (see table). Z-test was used to measure the 
difference between radiation receipt for those who had the 
test and those who did not. 
 
Results: Post-mastectomy radiation was delivered for 431 
patients (8.1%) of the 5302 included patients. Multivariate 
statistics were used to investigate potential radiation drivers 
including age, race, insurance status, grade, recurrence 
score, and presence of cells in the nodes on 
immunohistochemical staining (N0i+ versus N0i-). The 
strongest association with receipt of radiation therapy was 
N0i+ status (p<.002) versus N0. Age, race, insurance status, 
grade, and actual recurrence score did not predict for receipt 
of post-mastectomy radiation therapy. 
 
Conclusion: As expected, radiation was used in a minority of 
this cohort. Presence of cells in a lymph node was the largest 
driver, even though the disease burden in the nodes was very 
low to be T2N0i+. In patients where the recurrence score was 
ordered, it also predicted for non-receipt of radiation 
therapy as a rationale de-escalation of care. The biggest 
driver of radiation was Noi+ status, where at least a small 
number of cells reached the lymph nodes and radiation might 
be expected to have an impact. Interestingly, increasing 
recurrence score reflecting aggressive biology and poorer 
outcomes did not drive PMRT receipt in this population. In 
the future, use of the recurrence score may help select 
patients in whom personalized use of local therapy is 
possible.  
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Purpose or Objective: Regional radiotherapy (RT) is 
replacing axillary lymph node (LN) dissection in breast-cancer 
patients with tumor-positive sentinel node(s) (SNs). In 
regional RT, only part of the LNs can be visualized using 
